Construction of an anaplastic thyroid cancer stratification signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments
IntroductionWhile most thyroid cancer patients have a favorable prognosis, anaplastic thyroid carcinoma (ATC) remains a particularly aggressive form with a median survival time of just five months. Conventional therapies offer limited benefits for this type of thyroid cancer. Our study aims to ident...
Saved in:
| Main Authors: | Li Pengping, Yin Kexin, Xie Yuwei, Sun Ke, Li Rongguo, Wang Zhenyu, Jin Haigang, Wang Shaowen, Huang Yuqing |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1478904/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy
by: Zhao Zou, et al.
Published: (2025-07-01) -
Efficient delivery of anlotinib and radioiodine by long circulating nano-capsules for active enhanced suppression of anaplastic thyroid carcinoma
by: Linlin Zhang, et al.
Published: (2025-03-01) -
New opportunities for preoperative diagnosis of anaplastic thyroid cancer
by: S. A. Lukyanov, et al.
Published: (2021-04-01) -
Regressed Papillary Thyroid Carcinoma with Anaplastic Transformation into Lymph Node Metastasis: Case Report with Review of the Literature
by: Bozidar Kovacevic, et al.
Published: (2025-02-01) -
Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
by: D. M. Vontlaya, et al.
Published: (2024-06-01)